Market revenue in 2024 | USD 911.1 million |
Market revenue in 2035 | USD 4,225.1 million |
Growth rate | 14.1% (CAGR from 2025 to 2035) |
Largest segment | Ozempic (semaglutide) |
Fastest growing segment | Rybelsus (oral semaglutide) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 104.21% in 2024. Horizon Databook has segmented the China semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
China’s market is growing rapidly, supported by government policies promoting healthcare modernization and local biopharma expansion.
Increasing demand for diabetes and obesity treatments, coupled with the rise of online pharmacies, is transforming market accessibility. The country is seeing significant investments in GLP-1 receptor agonist research and manufacturing.
Horizon Databook provides a detailed overview of country-level data and insights on the China semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into China semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account